Clinical Performance Evaluation of a Rapid Near Patient Test for Influenza A and B

In an attempt to reduce time to diagnosis, Alere has developed the Alere™ i Influenza A & B; a rapid, molecular point of care test, which generates a diagnostic result in fifteen minutes or less. Rapid test results can lead to evidence-based and therefore more appropriate use of resources in terms of isolation and patient treatment. It is thought that this impact could be even greater in Trusts without laboratory facilities on site. An early positive diagnosis of influenza, in cases where bacterial infection may be suspected, could also promote and optimise antimicrobial stewardship. Initial results indicate that the implemented test can also bring about cost savings to NHS Trusts, when compared to real time-PCR.

Alere Influenza Test Case Study

Links to the Innovation Pathway: Markets; Evaluation; Brokering

(Uploaded on 10th August 2016)

Search the Innovation Exchange